Skip to main content

Table 5 Frequency and incidence of outcomesa,b among the IPF cohorts during follow-up

From: Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data

 

Restricted to Patients without the Condition during Baseline

 

IPF Cohort

(N= 4,716)

IPF Diagnostic Testing Subgroup

(N= 2,518)

 

Total Patients Eligible for Outcome

# of Patients with Outcome

Person-Years

IR

95% CI

Total Patients Eligible for Outcome

# of Patients with Outcome

Person-Years

IR

95% CI

Primary Outcomes

Acute Respiratory Worsening of Unknown Cause

4,590

110

5,803

19.0

15.6 - 22.8

2,392

61

2,915

20.9

16.0 - 26.9

Pulmonary Hypertension

4,497

260

5,654

46.0

40.6 - 51.9

2,357

145

2,862

50.7

42.8 - 59.6

Pulmonary Arterial Hypertension

4,706

13

5,976

2.2

1.2 - 3.7

2,513

6

3,062

2.0

0.7 - 4.3

Lung Transplantationc

4,706

6

5,980

1.0

0.4 - 2.2

2,516

3

3,074

1.0

0.2 - 2.9

Lung Cancer

3,959

130

5,003

26.0

21.7 - 30.9

2,025

80

2,431

32.9

26.1 - 41.0

Acute Myocardial Infarctiond

4,591

199

5,784

34.4

29.8 - 39.5

2,440

108

2,950

36.6

30.0 - 44.2

Acute Myocardial Infarctione

4,588

156

5,779

27.0

22.9 - 31.6

2,446

88

2,956

29.8

23.9 - 36.7

All-Cause Mortality

4,716

1,082

5,998

180.4

169.8 - 191.5

2,518

584

3,076

189.9

174.8 - 205.9

Secondary Outcomes

GI Perforation

4,705

30

5,952

5.0

3.4 - 7.2

2,512

15

3,058

4.9

2.7 - 8.1

Chronic Renal Failure/Insufficiency

3,466

633

4,141

152.9

141.2 - 165.2

1,800

315

2,092

150.6

134.4 - 168.2

Hemorrhagic Diathesis or Coagulopathy

4,596

135

5,763

23.4

19.6 - 27.7

2,438

73

2,939

24.8

19.5 - 31.2

Venous Thrombosis

4,412

259

5,454

47.5

41.9 - 53.6

2,328

151

2,755

54.8

46.4 - 64.3

Pulmonary Embolism

4,561

143

5,712

25.0

21.1 - 29.5

2,420

77

2,916

26.4

20.8 - 33.0

Strokef

4,537

187

5,631

33.2

28.6 - 38.3

2,427

96

2,895

33.2

26.9 - 40.5

Strokeg

4,637

129

5,778

22.3

18.6 - 26.5

2,479

64

2,963

21.6

16.6 - 27.6

Cardiac Arrhythmia

3,104

640

3,594

178.1

164.5 - 192.4

1,583

315

1,772

177.8

158.7 - 198.6

Congestive Heart Failure

3,221

641

3,948

162.4

150.0 - 175.4

1,669

322

1,981

162.5

145.3 - 181.3

Ischemic Heart Disease

2,810

494

3,197

154.5

141.2 - 168.8

1,445

249

1,569

158.7

139.6 - 179.7

Arterial Hypertension

1,117

401

1,071

374.3

338.6 - 412.8

577

197

516

382.0

330.5 - 439.2

Neutropenia

4,676

55

5,920

9.3

7.0 - 12.1

2,486

29

3,021

9.6

6.4 - 13.8

Pneumonia

4,280

382

5,294

72.2

65.1 - 79.8

2,232

189

2,670

70.8

61.0 - 81.6

Sepsis

4,471

348

5,610

62.0

55.7 - 68.9

2,368

166

2,873

57.8

49.3 - 67.3

COPD

2,288

607

2,457

247.1

227.8 - 267.5

1,131

298

1,150

259.1

230.5 - 290.2

GERD

3,395

565

3,657

154.5

142.0 - 167.8

1,757

289

1,814

159.3

141.5 - 178.8

Type 2 Diabetes Mellitus

3,183

234

3,947

59.3

51.9 - 67.4

1,672

121

2,003

60.4

50.1 - 72.2

Obstructive sleep apnea

4,333

176

5,329

33.0

28.3 - 38.3

2,294

94

2,703

34.8

28.1 - 42.6

Bronchitis

2,805

697

2,857

243.9

226.2 - 262.7

1,420

340

1,365

249.1

223.3 - 277.0

Upper Respiratory Tract Infection

4,265

337

4,960

67.9

60.9 - 75.6

2,252

181

2,504

72.3

62.1 - 83.6

Pulmonary Rehabilitation

4,640

130

5,773

22.5

18.8 - 26.7

2,466

85

2,934

29.0

23.1 - 35.8

Acute Coronary Syndrome

4,570

138

5,647

24.4

20.5 - 28.9

2,436

73

2,894

25.2

19.8 - 31.7

Angina Pectoris

4,460

151

5,493

27.5

23.3 - 32.2

2,365

81

2,795

29.0

23.0 - 36.0

Bleeding

4,149

550

4,758

115.6

106.1 - 125.7

2,199

274

2,434

112.6

99.7 - 126.7

Major GI Bleeding (Upper)

4,641

89

5,842

15.2

12.2 - 18.7

2,478

47

2,994

15.7

11.5 - 20.9

Major GI Bleeding (Lower)

4,404

311

5,325

58.4

52.1 - 65.3

2,338

165

2,727

60.5

51.6 - 70.5

Hemorrhage of the Rectum or Anus

4,598

129

5,708

22.6

18.9 - 26.9

2,449

65

2,915

22.3

17.2 - 28.4

Blood in Stool

4,589

164

5,663

29.0

24.7 - 33.7

2,456

85

2,920

29.1

23.3 - 36.0

Epistaxis

4,596

144

5,708

25.2

21.3 - 29.7

2,447

70

2,925

23.9

18.7 - 30.2

Hemorrhoids

4,610

114

5,725

19.9

16.4 - 23.9

2,461

57

2,941

19.4

14.7 - 25.1

Hemorrhoidal Bleeding

4,686

31

5,920

5.2

3.6 - 7.4

2,502

16

3,038

5.3

3.0 - 8.6

Intracranial Hemorrhage

4,677

58

5,913

9.8

7.4 - 12.7

2,499

35

3,021

11.6

8.1 - 16.1

Acute Pancreatitis

4,669

37

5,910

6.3

4.4 - 8.6

2,491

14

3,041

4.6

2.5 - 7.7

Hepatic Failure

4,702

22

5,990

3.7

2.3 - 5.6

2,511

11

3,072

3.6

1.8 - 6.4

Acute Renal Failure

4,101

506

5,189

97.5

89.2 - 106.4

2,140

261

2,630

99.2

87.6 - 112.0

Depression (MDD only)

4,141

398

4,964

80.2

72.5 - 88.5

2,203

208

2,531

82.2

71.4 - 94.1

Depression (MDD and other)

4,068

420

4,831

86.9

78.8 - 95.7

2,163

229

2,456

93.3

81.6 - 106.1

  1. Optum Research Database – Medicare Advantage Population
  2. Cohort Entry: 01 January 2008 - 30 September 2014
  3. Abbreviations: IR incidence rate per 1,000 person-years, CI confidence Interval, IPF idiopathic pulmonary fibrosis, COPD chronic obstructive pulmonary disease, GERD, gastroesophageal reflux disease, MDD major depressive disorder;
  4. aThe mean follow-up time was 0.8 years (IPF cohort) and 0.7 years subgroup)
  5. bOccurrence of one outcome did not preclude the occurrence of another, with the exception of all-cause mortality, which would result in censoring all additional follow-up
  6. cFor lung transplantation, patients with unilateral lung transplantation during the baseline period could be "at-risk" to receive another unilateral lung transplantation during the follow-up period; however, double lung transplantations during the baseline would preclude subsequent "at-risk" person-time during the follow-up period
  7. dPatients with 2+ claims with ICD-9 code of 410.x0 or 410.x1, primary position only. Patients with only one claim with these AMI codes but have claims suggestive of death were classified as AMI cases. Claims must be within 7 days of each other and must be from the inpatient or emergency room setting
  8. ePatients with an ICD-9-CM code for AMI (410.x0, 410.x1) in the principal (or primary) diagnosis position on at least one facility claim for hospitalization. Claims from emergency departments were not be included in the case identification as they are likely to lead to misclassification
  9. fICD-9 code 430, 431, 433.x1, or 434.x1, only in the primary or secondary diagnosis position. For patients identified by 430, 431, exclude if the following ICD-9 diagnosis codes are present on the same day: 800.xx-804.xx, 850.xx-854.xx (in any position); or V57.xx (in the primary position)
  10. gICD-9 code 430, 431, 433.x1 or 434.x1, restricted to the primary diagnosis position on at least 1 facility claim for hospitalization
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us